Kalaris Therapeutics Data From Phase 1a Single Dose Study Of TH103 Demonstrates Showed Mean 10-letter Gain In Visual Acuity, Rapid; TH103 Was Generally Well Tolerated

Kalaris Therapeutics, Inc. (NASDAQ:KLRS), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases, today announced positive initial data from its Phase 1a single ascending dose (SAD) trial of TH103, a fully humanized, recombinant fusion protein that acts against VEGF as a decoy receptor, in treatment-naïve patients with neovascular age-related macular degeneration (nAMD). The data demonstrate that TH103's engineered molecular properties translated into clinically meaningful improvements in vision and retinal anatomy, with early signals suggesting the potential for extended treatment durability. The initial data will be presented at 4:30 pm EST today via webcast.